Self-Administered Drug Exclusion List (A53033) - R42 - Effective June 1, 2025

Date Posted: April 17, 2025

This billing and coding article has been revised and published for notice under contract numbers: 02101 (AK), 02201 (ID), 02301(OR), 02401 (WA), 03101 (AZ), 03201 (MT), 03301 (ND), 03401 (SD), 03501 (UT), and 03601 (WY).

Effective Date: June 1, 2025

Summary of Changes:

Added: CPT/HCPCS codes Q9999 Injection, Ustekinumab-aauz (Otulfi), biosimilar, 1 mg*; J3490, J3590, C9399 lebrikizumab-lbkz (Ebglyss); and J3490, J3590, C9399 ustekinumab-stba (SteQeyma)*

Visit the Self-Administered Drugs (SADs) webpage to view the Self-Administered Drug Exclusion List.

To view the complete listing of billing and coding articles and/or access the Active, Future, or Retired articles available in the CMS MCD, visit the Billing and Coding Articles webpage.

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )